IPSEN (OTCMKTS:IPSEY) Sees Large Growth in Short Interest

IPSEN (OTCMKTS:IPSEY) saw a large increase in short interest during the month of May. As of May 15th, there was short interest totaling 514 shares, an increase of 73.1% from the April 30th total of 297 shares. Based on an average daily volume of 2,506 shares, the short-interest ratio is presently 0.2 days. Currently, 0.0% of the shares of the company are sold short.

IPSEN Trading Up 1.5%

IPSEN stock opened at $43.85 on Thursday. The firm has a 50 day simple moving average of $47.72 and a 200 day simple moving average of $42.61. IPSEN has a 1-year low of $28.66 and a 1-year high of $51.10.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on IPSEY shares. Zacks Research upgraded shares of IPSEN to a “hold” rating in a research note on Friday, May 29th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research note on Thursday, May 14th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).